With 1.55 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.72 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $34.0 whereas the lowest price it dropped to was $33.01. The 52-week range on ALKS shows that it touched its highest point at $36.45 and its lowest point at $22.90 during that stretch. It currently has a 1-year price target of $38.64. Beta for the stock currently stands at 0.38.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ALKS was down-trending over the past week, with a drop of -2.97%, but this was up by 5.19% over a month. Three-month performance surged to 7.38% while six-month performance rose 24.56%. The stock gained 17.55% in the past year, while it has gained 16.90% so far this year. A look at the trailing 12-month EPS for ALKS yields 2.18 with Next year EPS estimates of 1.87. For the next quarter, that number is 0.29. This implies an EPS growth rate of -37.03% for this year and 2.63% for next year.
Float and Shares Shorts:
At present, 162.18 million ALKS shares are outstanding with a float of 158.41 million shares on hand for trading. On 2025-02-28, short shares totaled 14.01 million, which was 861.0 higher than short shares on 1738281600. In addition to Mr. Richard F. Pops as the firm’s Chairman & CEO, Mr. Blair C. Jackson serves as its Interim Principal Financial Officer, Executive VP, Chief Risk Officer & COO.
Institutional Ownership:
Through their ownership of 1.05982 of ALKS’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-12-31, ALKS reported revenue of $429986000.0 and operating income of $162688000.0. The EBITDA in the recently reported quarter was $181384000.0 and diluted EPS was $nan.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ALKS since 8 analysts follow the stock currently. There are 6 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With ALKS analysts setting a high price target of 46.0 and a low target of 26.0, the average target price over the next 12 months is 37.8. Based on these targets, ALKS could surge 36.82% to reach the target high and fall by -22.67% to reach the target low. Reaching the average price target will result in a growth of 12.43% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $2.80705 being high and $2.39626 being low. For ALKS, this leads to a yearly average estimate of $2.62122. Based on analyst estimates, the high estimate for the next quarter is $0.56 and the low estimate is $0.39. The average estimate for the next quarter is thus $0.48.
